A Study to Investigate the Effects of GC4419 on Radiation-Induced Oral Mucositis in Patients With Head/Neck Cancer

Overview

Información sobre este estudio

The purpose of this study is to determine if GC4419, administered prior to intensity-modulated radiation therapy (IMRT), reduces the severity of radiation-induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria: 

  • Squamous cell carcinoma of the head and neck.
  • Treatment plan to receive IMRT delivered as single daily fractions of 2.0 to 2.2 Gy with a cumulative radiation dose of 60-72 Gy.
  • Treatment plan to receive standard cisplatin monotherapy.
  • Age 18 years or older.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Adequate hematologic, renal and liver function.
  • Negative serum pregnancy test.
  • Use of effective contraception.

Exclusion Criteria:

  • Tumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, or salivary glands.
  • Metastatic disease. 
  • Prior radiotherapy to the region of the study cancer or adjacent anatomical. 
  • Prior induction chemotherapy. 
  • Receiving any approved or investigational anti-cancer agent other than those provided for in this study. 
  • Concurrent participation in another interventional clinical study.
  • Inability to eat soft solid food at baseline.
  • Malignant tumors other than HNC within the last 5 years.
  • Active infectious disease excluding oral candidiasis. 
  • Presence of oral mucositis at baseline. 
  • Known history of HIV or active hepatitis B/C.
  • Female patients who are pregnant or breastfeeding. 
  • Known allergies or intolerance to cisplatin and similar platinum-containing compounds. 
  • Requirement for concurrent treatment with nitrates or other drugs that may create a risk for a precipitous decrease in blood pressure.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Byron May, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20467330

Mayo Clinic Footer